List view / Grid view
22 September 2022 | By bioMérieux
This webinar presents the regulatory submission strategy for implementation and validation of a new PCR-based technology for mycoplasma testing of different products.
According to researchers, the CRISPR-based gene therapy, EBT-101, has the potential to change the future of HIV therapeutics.
Evusheld becomes first and only long-acting antibody combination available for both prevention and treatment of COVID-19 in Europe.
Biosimilar medicines can now be interchanged with their reference medicine or an equivalent biosimilar, says European Medicines Agency (EMA).
Roche’s Vabysmo® (faricimab) has been approved in Europe as a four-monthly treatment for wet age-related macular degeneration and diabetic macular oedema.
Similar rates of skin improvement at week 100 indicate Skyrizi® (risankizumab) has consistent long-term efficacy in psoriatic arthritis patients.
Investing in a new production facility and carbon net-zero emissions warehouse in Lessines, Belgium, Takeda aims to expand access for rare and complex chronic disease treatments.
What unmet need remains in breast cancer and how is drug development helping tackle these challenges? Tune in to this episode with Daiichi Sankyo to find out more.
Dual checkpoint inhibitor blockade could be a promising first-line and salvage therapeutic option for advanced Merkel cell carcinoma, say researchers.
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-300x278.jpg)
![Novartis logo Novartis building in Stein, Switzerland [Credit: Taljat David shutterstock.com]](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/novartis-image-scaled-e1594985022657.jpg)
Investing $300mn, Novartis aims to support the growth and diversity of its biotherapeutics portfolio with technical capabilities to expedite early development.
US National Institutes of Health initiates trials to evaluate antiviral tecovirimat (TPOXX) and possibility of delivering Jynneos vaccine intradermally.
EPR highlights the implementation of multi angle light scattering (MALS) as a process analytical technology (PAT) tool for the real-time monitoring of protein-polysaccharide conjugate fraction molar mass.
Achieve digital lab transformation by becoming future ready with the 100% paperless lab requisites. Check the wish list for a better tomorrow lab.
A multi-wavelength UV-based process analytical technology (PAT) could significantly reduce downstream protein purification timelines.
Anytime PQR is the new way of generating APQR by automating the reports anytime in 3 easy steps. Now make the entire process system driven with CaliberAPQR.
